Homologous recombination deficiency testing in first-line ovarian cancer. | Ann Oncol;33(3): 231-233, 2022 03. | MEDLINE

Main content 1 Search 2 Footer 3

+A A -A High contrast

VHL Search Portal

Information and Knowledge for Health

Subject descriptor lookup Advanced Search

Homologous recombination deficiency testing in first-line ovarian cancer.

Moore, K N; du Bois, A.

Affiliation

Moore KN; Department of Obstetrics and Gynecology, Stephenson Cancer Center at the University of Oklahoma HSC, Oklahoma City, USA. Electronic address: Kathleen-moore@ouhsc.edu.
du Bois A; Department of Gynecology & Gynecologic Oncology, Evangelische Kliniken Essen Mitte (KEM), Essen, Germany.

Ann Oncol ; 33(3): 231-233, 2022 03.

Article in En | MEDLINE | ID: mdl-35017033

Subject(s)

Ovarian Neoplasms; Carcinoma, Ovarian Epithelial; Homologous Recombination; Humans; Ovarian Neoplasms/diagnosis; Ovarian Neoplasms/genetics

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Ovarian Neoplasms Type of study: Diagnostic_studies Limits: Humans Language: En Journal: Ann Oncol Journal subject: NEOPLASIAS Year: 2022 Type: Article

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Ovarian Neoplasms Type of study: Diagnostic_studies Limits: Humans Language: En Journal: Ann Oncol Journal subject: NEOPLASIAS Year: 2022 Type: Article